Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30

Vaccine Against Human Papilloma Virus - Abstract Show Comments PDF Print E-mail
  
Monday, 23 March 2009

Hospital General de Zona 1, lnstituto Mexicano del Seguro Social (IMSS) Facultad de Medicina, Universidad de Colima, Colima, México.

This email address is being protected from spam bots, you need Javascript enabled to view it

Genital human papilloma virus infection (HPV) is the most common sexually transmitted infection worldwide, it is the cause of genital warts, and it is related with cervical cancer, the second most common cause of death from cancer in women in America, and the first in underdeveloped countries, and it is related with penis and prostate cancer in males also, and with anal cancer in both genders. This review examines the most important actual facts about HPV infection, and the new prophylactic vaccines. Two versions of the vaccine had been developed, both target HPV 16 and HPV 18, which involve approximately 70% of cervical cancer. One of them also targets HPV 6 and HPV 11, which account for approximately 90% of external genital warts. Both vaccines have an excellent safety profile, are highly immunogenic, and have atributed complete type specific protection against persistent infection and associated lesions in fully vaccinated girls and young women. The role of men as carriers of HPV as well as vectors for transmission is well documented. Several clinical trials are currently under way to determine the efficacy of vaccinating men. Reducing the cost of vaccination would be a priority for the developing world in order to get a broad target in poor countries.

Article in Spanish

Written by:
Juárez-Albarrán AC, Juárez-Gámez CA. Are you the author?

Reference:
Rev Med Inst Mex Seguro Soc. 2008 Nov-Dec;46(6):631-7.

PubMed Abstract
PMID:19263667

UroToday.com Sexually Transmitted Disease Section

 

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 6
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
4 (2 votes)

Patients:
5 (2 votes)

No Affiliation:
4 (2 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

Penis & Urethra Cancer
Sponsored By